Holen Sie sich die Stockscreener-App
0.6318
0.69%
0.0043
Handel nachbörslich:
.65
0.0182
+2.88%
Schlusskurs vom Vortag:
$0.6275
Offen:
$0.629
24-Stunden-Volumen:
95,718
Relative Volume:
0.41
Marktkapitalisierung:
$59.97M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.15M
KGV:
-0.6943
EPS:
-0.91
Netto-Cashflow:
$-31.63M
1W Leistung:
-3.51%
1M Leistung:
+7.45%
6M Leistung:
-46.91%
1J Leistung:
-65.66%
1-Tages-Spanne:
$0.622
$0.6594
1-Wochen-Bereich:
$0.616
$0.70
52-Wochen-Spanne:
$0.49
$2.75
Context Therapeutics Inc Stock (CNTX) Company Profile
Firmenname
Context Therapeutics Inc
Sektor
Branche
Telefon
267-225-7416
Adresse
2001 MARKET STREET, PHILADELPHIA
Vergleichen Sie CNTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.6318 | 59.97M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-21 | Eingeleitet | William Blair | Outperform |
| 2025-01-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-11-25 | Eingeleitet | D. Boral Capital | Buy |
| 2024-05-16 | Eingeleitet | Piper Sandler | Overweight |
Context Therapeutics Inc Aktie (CNTX) Neueste Nachrichten
Citadel Advisors LLC Makes New $31,000 Investment in Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
Millennium Management LLC Purchases 34,835 Shares of Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
Context Therapeutics Approves Reverse Stock Split Amendment - TipRanks
Context Therapeutics Names Dr. Karen Chagin as Chief Medical Officer - MSN
Co-Founder of Context Therapeutics Martin Lehr Buys 10% More Shares - simplywall.st
Context Therapeutics Executives Increase Holdings - TradingView
Context Therapeutics: Undervalued Cancer Fighter (NASDAQ:CNTX) - Seeking Alpha
Jane Street Group LLC Makes New $29,000 Investment in Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
CNTXContext Therapeutics Reports First Quarter 2025 Operating and Financial Results - mx.advfn.com
Northern Trust Corp Sells 58,946 Shares of Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
Context Therapeutics Inc. Advances CTIM-76 in Phase 1 Trial for Solid Tumors with Initial Data Expected in 2026 - Nasdaq
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting - GlobeNewswire
Context Therapeutics' Cancer Drug CTIM-76 Progresses in Phase 1 Trial: Key Updates from ASCO 2025 - Stock Titan
Context Therapeutics names new CMO to advance T cell therapies By Investing.com - Investing.com South Africa
Context Therapeutics (CNTX) Names New Chief Medical Officer | CN - GuruFocus
Context Therapeutics (CNTX) Names New Chief Medical Officer | CNTX Stock News - GuruFocus
Context Therapeutics names new CMO to advance T cell therapies - Investing.com
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer - GlobeNewswire
Context Therapeutics Appoints Developer of First FDA-Approved Solid Tumor Cell Therapy as Chief Medical Officer - Stock Titan
Context Therapeutics Grants Stock Options to New Hires as Part of Strategic Talent Growth - MSN
Context Therapeutics Names Dr. Karen Smith as Interim Chief Medical Officer - MSN
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.40 Consensus Price Target from Analysts - Defense World
Context Therapeutics Reports Q1 2025 Financial Results and Clinical Progress - MSN
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
William Blair Has Positive Outlook of CNTX FY2025 Earnings - Defense World
Research Analysts Offer Predictions for CNTX Q2 Earnings - Defense World
D. Boral Capital Reaffirms “Buy” Rating for Context Therapeutics (NASDAQ:CNTX) - Defense World
UTR Therapeutics files IND application for UTRxM1-18 for c-MYC-driven cancers - BioWorld MedTech
Context Therapeutics Showcases Promising CT-95 Data at AACR Annual Meeting - MSN
Context Therapeutics (CNTX) Receives Continued 'Buy' Rating from Analyst | CNTX Stock News - GuruFocus
FORE Biotherapeutics’ Plixorafenib Study to Be Highlighted at ASCO 2025 - MyChesCo
CONTEXT THERAPEUTICS Earnings Results: $CNTX Reports Quarterly Earnings - Nasdaq
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results - GlobeNewswire
Marshall Wace LLP Buys New Stake in Context Therapeutics Inc. (NASDAQ:CNTX) - The AM Reporter
Context Therapeutics Appoints Karen Smith as Interim CMO - citybiz
Context Therapeutics (CNTX) Names Karen Smith as Interim Chief Medical Officer | CNTX Stock News - GuruFocus
Context Therapeutics appoints new interim CMO - Investing.com
Context Therapeutics appoints new interim CMO By Investing.com - Investing.com South Africa
Context Therapeutics Announces Chief Medical Officer Transition - GlobeNewswire
Context Therapeutics Inc Announces Executive Changes Effective May 10, 2025 - marketscreener.com
Renaissance Technologies LLC Boosts Stock Holdings in Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
What is William Blair’s Estimate for CNTX Q2 Earnings? - Defense World
Context Therapeutics Inc. (NASDAQ:CNTX) Stock Holdings Boosted by Geode Capital Management LLC - Defense World
Context Therapeutics’ (CNTX) Outperform Rating Reiterated at William Blair - Defense World
Context Therapeutics’ (CNTX) Buy Rating Reiterated at D. Boral Capital - Defense World
Finanzdaten der Context Therapeutics Inc-Aktie (CNTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Context Therapeutics Inc-Aktie (CNTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Levit Alex C. | Chief Legal Officer, Corp. Sec |
Jun 06 '25 |
Buy |
0.58 |
20,000 |
11,520 |
29,000 |
| Minai-Azary Jennifer Lynn | Chief Financial Officer |
Jun 06 '25 |
Buy |
0.64 |
40,010 |
25,486 |
80,010 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):